UCB expands discovery accord with BioSeek

BioSeek, a US drug discovery firm specializing in predictive human biology, has entered into a new and expanded agreement with Belgian  drugmaker UCB.

Under the terms of the deal, BioSeek will, over the coming year, both  carry out broad-based profiling of selected UCB new chemical and  biological entities, and guide lead optimization of a specific  phenotypic hit previously identified by UCB and further characterized in  BioMAP screens.

BioSeek will receive various payments from UCB, including an upfront  technology license fee, research funding and preclinical and clinical  milestone payments based on candidate advancement enabled by the BioMAP  platform. Further financial terms were not disclosed.